Johnson & Johnson announced that it will begin an exploratory process to evaluate strategic alternatives for its Ortho Clinical Diagnostics (OCD) business. All options will be evaluated to determine the best opportunity for future growth and maximize shareholder value. The various alternatives include a possible divestiture if it is determined that OCD could have greater potential as part of another organization or by operating as a stand-alone company.

There is no guarantee whether a transaction will be consummated. Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson said, "As we look to the future we're advancing innovative new products in our pipeline, continuing to take a disciplined approach to managing our portfolio and adapting our business to the changing marketplace."